Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study

BACKGROUND: In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR testing unavailability, the Severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Segala, Francesco Vladimiro, Rando, Emanuele, Salvati, Federica, Negri, Marcantonio, Catania, Francesca, Sanmartin, Flavia, Murri, Rita, Giamarellos-Bourboulis, Evangelos J., Fantoni, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072376/
https://www.ncbi.nlm.nih.gov/pubmed/37014833
http://dx.doi.org/10.1371/journal.pone.0273202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072376/
https://www.ncbi.nlm.nih.gov/pubmed/37014833
http://dx.doi.org/10.1371/journal.pone.0273202

Ejemplares similares